ZOTA logo

Zota Health Care LImited

ZOTA·NSE·
₹1,412.70▲ +44.40 (+3.24%)
Market Cap4880.77 Cr
PE Ratio-36.50
Volume40,785
Day High - Low1419.90 - 1351.10
52W High-Low1740.00 - 1022.00

Zota Health Care LImited (ZOTA): company summary

The company's revenue grew by 84.5% annually, but net profit turned into a loss, widening from a ₹57 crore loss to a ₹74 crore loss.

Zota Health Care LImited (ZOTA) is a micro-cap Healthcare company valued at ₹4,881 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move
Zota Health Care LImited last traded at ₹1,412.7, up 3.24% on the day.
Recent developments
On 2026-09-21, the company announced a dividend of ₹1.00 per share, with the ex-date set for that date. Promoter holding remained at 49.38% as of 2026-06-30, with 0.26% of promoter shares pledged. Domestic institutional holding decreased by 0.29 percentage points to 6.75%.
Financial performance
The company's revenue grew by 84.5% annually, but net profit turned into a loss, widening from a ₹57 crore loss to a ₹74 crore loss. The latest quarter saw revenue rise 66.9% year-on-year, but the net loss widened from ₹14 crore to ₹44 crore, with the net profit margin improving slightly to -13.8% from -19.5%.
Valuation multiples
A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at 5.49 times book value.
Things to watch
The company reported a net loss of ₹74 crore in its latest financial year, with the loss widening from ₹57 crore the previous year. The latest quarter's net loss widened from ₹14 crore to ₹44 crore, and return on equity and return on capital employed remain negative at -10.7% and -8.7% respectively.
Where it stands
The company's revenue has grown rapidly, but net profit remains in loss, with the latest quarter's loss widening significantly. The stock is 27.1% below its 52-week high, and the net profit margin improved slightly despite the loss. The company's debt-to-equity ratio is almost debt-free at 0.04.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score
2.9/10
Poor
Fair Value
Sign in to see
ROE
-10.66%
Weak
P/E
-36.50x
Loss-making
Debt / Equity
0.04
Low
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed

Price performance

Day₹1351
₹1420
52W₹1022
₹1740
DocStoX take

Supported by growth (7.5) and risk (6.0), but held back by valuation (0.0). Growth looks strong at 7.5, but that is offset by valuation at 0.0 and quality at 0.7. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence
2.9
/10
Poor
Quality
Weak
ROE -10.7%
Valuation
Expensive
P/B 5.5× on assets (no earnings to value)
Growth
Strong
Revenue +38.4% 5Y CAGR
Risk
Moderate
D/E 0.04
Momentum
Firm
54% of 52-week range

At a glance

Market Cap
₹4,881 Cr
52W High / Low
₹1740 / ₹1022
Dividend Yield
0.09%
Promoter Holding
49.38%
EPS (TTM)
₹-22.46
Book Value
₹200.24

Key highlights

  • Revenue compounding 38% a year
  • Low leverage — D/E 0.04
  • Loss-making — no meaningful P/E
  • Loss-making in some of the last 5 years
2 Positives4 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Zota Health Care LImited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.